(MENAFN Editorial) WATERTOWN, Mass., Dec. 06, 2017 (GLOBE NEWSWIRE) -- (NASDAQ:) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will participate in a fireside chat discussion at the BMO Capital Markets 2017 Prescriptions for Success in Healthcare Conference on Thursday, December 14 at 4:00 p.m. Eastern Time at the Westin New York Grand Central Hotel in New York City.

Live audio webcasts of the presentation will be available on the company's website at . Archived presentations will be available for 30 days.

About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant (MDR) bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes three antibiotic clinical candidates: eravacycline, which is in phase 3 clinical trials, and TP-271 and TP-6076, which are in phase 1 clinical trials. Please visit for more company information.

Investor Contact:
Argot Partners
Maeve Conneighton
206-899-4940

Media Contact:
Sam Brown Inc.
Mike Beyer
312-961-2502

MENAFN0612201700703653ID1096196009